European Commission Grants Marketing Authorization for Jyseleca® ? for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis Biotech Investing
FDA Approves Bausch + Lomb Alaway® Preservative Free Ophthalmic Solution, 0.035% Medical Device Investing
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug Application for Phase II/III COVID-19 Trial Biotech Investing
Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial Biotech Investing
Bausch Health Announces VYZULTA® , 0.024%, is Now Approved In Seven Countries Medical Device Investing
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations Pharmaceutical Investing
